Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
Sunday, January 11, 2015 - 23:50
in Health & Medicine
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study.